Integrate & Innovate, Spanning Development
Yiling Pharmaceutical was established on June 16th, 1992. Originally it was only a small clinic called “Shijiazhuang Development Zone Medical Research Institute”. After years of fast development, it has grown into a listed company in Shenzhen Stock Exchange with 7 billion Yuan of net asset and 30 billion Yuan of market value. As a company with more than 10,000 employees, Yiling Pharmaceutical has made a protruding contribution to social and economic development. Due to the comprehensive strength, Yiling Pharmaceutical has won many honorary titles such as National Key Hi-tech Enterprise, Top 20 Listed Pharmaceutical Company, etc. Yiling Trademark has won the title of “China Famous Brand”.
From a small clinic in 1992 to a large pharmaceutical company, Yiling Pharmaceutical has successfully integrated its businesses of hospital, medicine and comprehensive health, and realized a leapfrog development. Look back on the development course, for every five years, a big change was achieved.
1992-1997
Concentrate on Health & Create Welfare for Mankind
1992-1997, Concentrate on Health and Create Welfare for Mankind. This period, a Five-in-One Development Mode was adopted, the company tenet and development aim were formulated. The production and market access of Tongxinluo Capsules brought about the first leap, businesses extended from hospital to drug production.
1997-2002
Concentrate on Health & Create Welfare for Mankind
1997-2002, Powered by Science and Technology, Oriented to the Market. The setting up of development strategy, the establishment and incessant improving of scientific innovative system, the build-up of a sales network that covers all China, laid a solid foundation for our development. This period, Tongxinluo Capsules won the 2nd Prize of the National Science and Technology Progress Awards, and was listed in the A List of the Catalogue of Drugs for Basic National Medical Insurance.
2002-2007
Concentrate on Health & Create Welfare for Mankind
2002-2007, Rely on Science and Technology to Develop a Series of Drugs. The construction of a 120,000 square meters of modern scientific research & production base indicated that mass production was realized, Yiling’s development sped up on a highway. With the guidance of Luobing Theory, a series of patent new drugs were developed, a good products array was formed. Now our products include 11 patent drugs, 10 clinically approved formulations, 20 formulations in clinical trials, more than 100 in-hospital preparations.
2007-2012
Concentrate on Health & Create Welfare for Mankind
2007-2012, the Planning of “Domestic Market as the Base, Connect with International Market, Integrate and Innovate, Spanning Development” was made, modern enterprise management system was established and improved. 6 new patent drugs were included in the Catalogue of Drugs for Basic National Medical Insurance. Sales revenue was doubled. Workshops that met international standards were built up and granted GMP certificates from US and Europe. The bell ringing of Shenzhen Stock Exchange announced the birth of Yiling Stocks. This period laid a solid foundation for Yiling’s spanning development.
2012-2017
Concentrate on Health & Create Welfare for Mankind
2012-2017, Oriented to Market, Driven by Science and Technology, Integrate and Innovate, Business Size Leap-forward. Chinese herbal drugs, chemical and biological drugs, capital operation, medical service, comprehensive health products, these five types of businesses were finely integrated, which signifies that Yiling Pharmaceutical had successfully enlarged its businesses from medical service to drugs production and to manufacturing of varieties of health products.
2017-Now
Concentrate on Health & Create Welfare for Mankind
2017-Now, “The Building of Chinese Medicine's Vessel Collateral Theory and Its Guidance for the Prevention and Treatment of Microvascular Lesions” has won the First Prize of the National Science and Technology Progress Awards, which marks an international breakthrough in the treatment of microvascular lesions. Lianhua Qingwen Capsules, an innovative herbal medicine of Yiling Pharmaceutical, has played an important role in prevention and treatment of Covid-19, and has been launched in more than 20 countries.